Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells 450 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the sale, the director now directly owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This trade represents a 6.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $601.06 on Friday. The company has a market cap of $45.83 billion, a P/E ratio of 155.31, a PEG ratio of 14.19 and a beta of 1.04. The firm has a fifty day moving average price of $593.68 and a 200 day moving average price of $440.17. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a 12 month low of $241.72 and a 12 month high of $698.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AXON. Geode Capital Management LLC lifted its stake in Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after purchasing an additional 35,320 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 12.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after buying an additional 127,769 shares during the last quarter. Champlain Investment Partners LLC boosted its holdings in shares of Axon Enterprise by 13.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock valued at $272,695,000 after buying an additional 83,265 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Axon Enterprise by 1.6% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after buying an additional 9,090 shares during the last quarter. Finally, Groupama Asset Managment acquired a new stake in Axon Enterprise during the 3rd quarter worth $200,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on AXON. Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Needham & Company LLC boosted their price objective on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. JMP Securities increased their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 31st. Northland Securities boosted their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, Robert W. Baird increased their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $488.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.